ProQR Therapeutics N.V. (NASDAQ:PRQR) has been assigned a consensus rating of “Hold” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $14.15.

Several research firms recently commented on PRQR. Zacks Investment Research upgraded ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Tuesday, August 22nd. ValuEngine upgraded ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th.

A number of hedge funds have recently modified their holdings of PRQR. Sphera Funds Management LTD. raised its holdings in ProQR Therapeutics N.V. by 65.0% during the 1st quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock valued at $1,650,000 after acquiring an additional 130,000 shares during the period. Janus Henderson Group PLC bought a new stake in ProQR Therapeutics N.V. during the 2nd quarter valued at $2,028,000. Artal Group S.A. raised its holdings in ProQR Therapeutics N.V. by 25.0% during the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after acquiring an additional 100,000 shares during the period. Finally, Redmile Group LLC raised its holdings in ProQR Therapeutics N.V. by 2.8% during the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after acquiring an additional 43,050 shares during the period. 35.93% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics N.V. (PRQR) opened at 5.40 on Friday. The company’s market cap is $130.17 million. The stock’s 50 day moving average price is $5.03 and its 200-day moving average price is $4.91. ProQR Therapeutics N.V. has a 52 week low of $3.65 and a 52 week high of $8.70.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/09/proqr-therapeutics-n-v-prqr-given-consensus-rating-of-hold-by-analysts.html.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.